Does the addition of norethindrone acetate to leuprolide acetate for ovarian suppression have no adverse effect on ovarian stimulation?
The addition of NETA does not attenuate COH in women undergoing IVF.
Our data suggest PAR1 overexpression may be involved in the development of metastases in breast cancer patient and is associated with undifferentiated cellular progression of the tumor. Further studies are needed to understand PAR1 mechanism of action and in a near future assay its potential use as risk factor for metastasis development in high grade breast cancer patients.